Moderna cancer vaccine steps closer to clinic use after late-stage trial milestone

Moderna and Merck said their personalised mRNA cancer vaccine cut melanoma recurrence and spread in a late-stage trial. The result marks a significant step for mRNA-based cancer treatment and sparked a sharp market reaction.Personalised mRNA cancer vaccine cuts melanoma recurrence risk by 49%Moderna and Merck’s personalised mRNA cancer vaccine, used with Keytruda, has shown positive late-stage trial results in high-risk melanoma, marking a major milestone in the development of personalised cancer treatment.Moderna and Merck have reported encouraging results from a late-stage clinical trial of a personalised mRNA cancer vaccine designed to reduce the risk of melanoma returning or spreading after surgery. The vaccine, known as antisera, was tested in combination with Merck’s widely used immunotherapy drug Keytruda (pembrolizumab).The companies said the treatment met its primary goal of reducing the risk of cancer recurrence and also achieved a secondary goal of lowering the risk of melanoma spreading to other parts of the body. Detailed results are expected to be presented at an upcoming medical meeting.The findings represent a significant development in the emerging field of mRNA cancer vaccines, which are designed to train a patient's immune system to identify and attack cancer cells based on mutations found in an individual’s tumour. WHAT IS A PERSONALISED MRNA CANCER VACCINE?Unlike traditional vaccines designed to prevent infections, personalised mRNA cancer vaccines are developed specifically for an individual patient. After a tumour is surgically removed, its genetic mutations can be analysed to identify targets that may help the immune system recognise remaining cancer cells.Moderna’s vaccine uses mRNA technology to provide the immune system with instructions related to these tumour-specific mutations. The goal is to stimulate an immune response capable of recognising and destroying cancer cells before they can grow or spread. The approach is part of a broader effort to develop personalised cancer treatment and more targeted forms of immunotherapy.KEYTRUDA PLUS PERSONALISED CANCER VACCINE SHOWS PROMISEThe Phase 3 trial enrolled 1,137 patients with high-risk stage IIB to IV melanoma whose tumours had been surgically removed. Participants were randomly assigned to receive either Keytruda combined with the personalised mRNA vaccine or Keytruda alone for approximately one year.According to the companies, the combination achieved both the trial's primary endpoint of reducing recurrence and its secondary endpoint of reducing the risk of distant metastasis, or cancer spreading to other parts of the body.The companies also reported that no new safety signals had emerged from the trial.The results are particularly important because Keytruda is already an established treatment for melanoma. Demonstrating that a personalised cancer vaccine can improve outcomes when added to an existing immunotherapy could strengthen the case for combining mRNA technology with cancer immunotherapy.A MAJOR MILESTONE FOR MRNA CANCER TREATMENTThe companies described the findings as the first positive late-stage results for an individualised mRNA cancer vaccine. The results could represent an important step toward using personalised vaccines as part of routine cancer care.Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, said the findings could mark the beginning of a new phase in immunotherapy for solid tumours.Moderna President Stephen Hoge said the companies are already discussing the treatment with regulators. Because the therapy has received breakthrough therapy designation, the companies believe it could potentially become available as early as next year, subject to regulatory approval.However, the companies have not yet released the full detailed trial data, and results for overall survival—whether the treatment helps patients live longer are still pending.EARLIER RESULTS STRENGTHENED EXPECTATIONSThe latest findings build on results from an earlier-stage study. In January, Moderna and Merck reported five-year data suggesting that the combination reduced the risk of recurrence or death by 49% compared with Keytruda alone.The new late-stage results provide further evidence that personalised mRNA vaccines could have a role in preventing cancer from returning after surgery.Researchers and pharmaceutical companies are also studying similar personalised cancer vaccine approaches in other cancers, including lung, breast and pancreatic cancer.WHAT COULD THIS MEAN FOR MELANOMA PATIENTS?Melanoma is the most serious form of skin cancer and can become difficult to treat when it spreads. For patients with high-risk melanoma who have already undergone surgery, preventing recurrence is a major treatment goal.A personalised cancer vaccine could potentially offer an additional layer of protection by helping the immune system recognise cancer cells carrying specific mutations from the patient's tumour.However, the treatment is still under regulatory review, and more detailed clinical data are needed before its long-term benefits and risks can be fully assessed.THE FUTURE OF PERSONALISED CANCER VACCINESThe success of Moderna and Merck's trial could have implications well beyond melanoma. If the approach continues to demonstrate safety and effectiveness, personalised mRNA cancer vaccines could become an important component of precision oncology.Researchers are now exploring whether similar vaccines can be developed for a range of solid tumours. The broader goal is to move cancer treatment toward therapies that are increasingly tailored to the unique genetic characteristics of each patient's tumour.For Moderna, the results also represent an important development as the company seeks to expand its mRNA technology beyond COVID-19 vaccines. For Merck, the combination could potentially extend the role of Keytruda in cancer treatment as the drug approaches patent-related challenges later this decade.While questions remain about manufacturing, scalability, pricing and long-term survival benefits, the positive late-stage results mark a potentially important step forward for personalized cancer treatment and mRNA cancer vaccine research.- EndsPublished By: Apoorva AnandPublished On: Aug 20, 2026 09:41 IST